Meniscus Tears: What the Evidence Actually Supports

Two different injuries share one name. Which one you have determines everything — including whether any treatment at all is likely to help.

Start Here: Which Tear Do You Have?

Almost every confusing thing written about meniscus tears comes from running two different injuries together. They are treated differently, they heal differently, and the research says opposite things about them³.

⚠️ An important exception, because it applies directly to runners: horizontal cleavage tears in young athletes are treated as a special case and warrant repair rather than removal — because a meniscectomy in a young active knee is inevitably extensive³.

⚠️ And a caution about MRI: degenerative meniscal lesions are frequently found on scans of middle-aged and older people³. Finding one does not establish that it is the source of your pain, and a scan finding is not by itself a reason to treat.

If you are not sure which you have, that is the first question to answer — before anyone discusses treatment with you.

The Problem: When Running Stops

For runners and active adults, a meniscus tear threatens routine, identity, and the simple pleasure of movement. The immediate fear is rarely the injury itself — it is the prospect of never running again.

Traditional pathways often present a binary: surgery now, or surgery later. In fact the evidence supports a wider set of options than that, and for a large group of patients the best-supported first step is not an operation at all.

This article sets out what is genuinely established, what is contested, and where our own treatment stands — including where it stands on evidence that is much thinner than the marketing around it suggests.

Understanding Meniscus Tears

Anatomy and Function

The menisci are two crescent-shaped pads of fibrocartilage — medial and lateral — sitting between femur and tibia. Their roles in load distribution, force transmission, shock absorption, joint stability, lubrication and proprioception are well established¹. The commonly cited figure is that the menisci transmit roughly 50-70% of the compressive load across the knee.

Losing meniscal tissue matters for a straightforward biomechanical reason: removing it concentrates load onto the articular cartilage. Meniscectomy has been identified as significantly accelerating joint degradation and is no longer a preferred treatment for meniscal tears².

The Red Zone vs. White Zone — the real mechanism story

Healing capacity is governed by blood supply, and the meniscus has three zones¹:

The inner two-thirds of the meniscus is both avascular and aneural¹. Without blood supply, a tear there cannot recruit the cells and signals that healing requires. This is a real anatomical constraint, and it is the honest basis for interest in biological augmentation — the idea being to supply what the tissue cannot supply itself.

⚠️ It is a rationale, not a result. "The tissue lacks blood supply, therefore adding cells will fix it" is a hypothesis. What happened when it was tested in humans is in the regenerative section below, and it is a more mixed picture than the rationale predicts.

Types of Meniscus Tears

By pattern:

• Horizontal cleavage — parallel to the tibial plateau; usually degenerative (special case: young athletes, see above)
• Vertical / longitudinal — perpendicular; often repairable
• Radial — cuts across the circumferential fibres, disrupting hoop stress
• Bucket-handle — a displaced longitudinal fragment; causes mechanical locking
• Complex — multi-pattern, usually degenerative
• Root tear — avulsion of the attachment; biomechanically similar to losing the whole meniscus

By location: posterior horn is the most common site for sports-related tears; anterior horn is less often injured; body/mid-substance tears are frequently degenerative.

Treatment Options: What the Randomised Evidence Shows

The surgery has been tested against a placebo operation — and did not beat it

This is the single most important body of evidence about meniscus tears, and it is worth stating precisely.

*FIDELITY (Sihvonen et al., New England Journal of Medicine, 2013)⁴ randomised 146 patients aged 35-65 (mean 52) with a symptomatic degenerative medial meniscus tear confirmed on both MRI and arthroscopy, and no knee osteoarthritis, to either arthroscopic partial meniscectomy or sham surgery*. Patients and outcome assessors were blinded. At 12 months, intention-to-treat:

No significant difference on any primary outcome. Every point estimate favours the sham operation. Both groups improved substantially — which tells you how much of the benefit attributed to this surgery is the natural course of the condition plus the experience of being treated.

At five years⁵, the clinical picture was unchanged (WOMET −1.7, 95% CI −7.7 to 4.3; Lysholm −2.1, −6.8 to 2.6), and there was a consistent, slightly greater risk of radiographic osteoarthritis progression in the surgical group (increase in Kellgren-Lawrence grade ≥1: absolute risk difference 13%, 95% CI −2% to 28%; OARSI sum score 0.7, 0.1 to 1.3).

On five-year MRI⁶, osteophyte progression was more likely after meniscectomy than after placebo surgery (odds ratio 2.86, 95% CI 1.16 to 6.21), while cartilage damage (1.31, 0.81 to 1.94) and bone marrow lesions (1.43, 0.84 to 2.43) did not differ significantly.

*METEOR (Katz et al., NEJM, 2013)⁷ asked a related question in 351 patients aged 45+ with a meniscal tear and* mild-to-moderate osteoarthritis: surgery plus physiotherapy, or physiotherapy alone. WOMAC physical function at 6 months improved 20.9 points (95% CI 17.9-23.9) with surgery and 18.5 (15.6-21.5) with physiotherapy — difference 2.4 points (95% CI −1.8 to 6.5). Results at 12 months were similar.

⚖️ The honest counterweight, and it is a real one: 30% of patients assigned to physiotherapy alone had surgery within six months. Physiotherapy did not satisfy everyone, and the trial cannot tell you how those patients would have fared without the option. This is the strongest argument available for the operation, and it belongs in the picture.

The guidelines followed the trials. An international panel issued a strong recommendation against arthroscopic surgery in nearly all patients with degenerative knee disease⁸. The 2024 ESSKA-AOSSM-AASPT consensus — 67 experts across 14 countries — addressed prevention, non-operative treatment of both acute and degenerative lesions, and return to sport⁹; its authors note that the underlying evidence is of low to moderate quality, with most recommendations at Grade C or D.

What this does and does not mean

✅ It means: if you have a degenerative meniscal lesion, arthroscopic meniscectomy is unlikely to help you more than a placebo operation would, and non-operative treatment is the appropriate first line^3,8.

✅ It also means: the case against removing meniscal tissue is stronger than a simple outcome comparison suggests — because it now rests on a placebo-controlled trial showing more radiographic degeneration after surgery than after sham^5,6.

❌ It does not mean surgery never works. These trials studied degenerative tears. They say nothing about a locked knee from a bucket-handle tear, an unstable displaced fragment, or a repairable traumatic tear in a young athlete — where repair remains well supported³.

❌ And it does not mean that because this operation is ineffective, something else must be effective. That inference is not available. Each treatment has to earn its own evidence, including ours.

Conservative management

For degenerative lesions this is first-line treatment, not a holding pattern^3,8:

• Structured exercise therapy and progressive loading
• Activity modification
• Weight management where relevant
• Simple analgesia and NSAIDs for symptom control
• Intra-articular corticosteroid injection for short-term symptom relief

Meniscectomy and repair, where surgery IS indicated

Where a tear is genuinely repairable, the evidence favours repairing rather than removing.

A systematic review of six studies and 298 patients with posterior medial meniscus injuries found¹⁰:

• Osteoarthritis progression: 51.4% after meniscectomy vs 21.3% after repair
• IKDC function: 67.6 vs 74.7 · Lysholm: 74.6 vs 83.8, both favouring repair

⚠️ How much weight this can carry: the review's authors state that the pooled data must be read with the heterogeneity of the included studies in mind. These were not randomised comparisons — patients selected for repair are systematically younger with better tissue and more favourable tear patterns, and some of the difference in outcome will follow from that rather than from the operation. The direction of the finding is consistent with the sham-controlled data^5,6; the size of it should be treated with caution.

Return to sport after surgery

From a review of meniscus surgery in athletes¹¹:

• After repair, athletes typically return to sport at 4-6 months; a meta-analysis by Totlis and colleagues found a 90% return-to-play rate¹¹
• After meniscectomy, symptoms often persist: 22% of athletes after medial meniscus surgery and 53% after lateral meniscus surgery had pain and/or effusion after returning to sport¹¹
• Lateral meniscectomy fares distinctly worse than medial: 69% of the lateral group had adverse events related to pain and swelling, versus 8% of the medial group¹¹
• In collegiate American football players, osteoarthritis prevalence was 27% after meniscectomy versus 11% after repair¹¹
• Isolated tears heal less well than those repaired alongside ACL reconstruction: 91% healing with concurrent ACL reconstruction versus 50% for isolated tears¹¹

Regenerative Therapy: Where It Genuinely Stands

The rationale

Mesenchymal stem cells have been studied for meniscal healing because they modulate the local inflammatory environment, secrete trophic factors, and can be directed toward fibrochondrocyte lineages¹. Sources under investigation include bone marrow, synovium, adipose tissue and umbilical cord.

⚠️ The mechanistic work supporting all of this is preclinical. The systematic review this page draws on for mechanism examined MSC application in vitro and in animal models, and states its own conclusion plainly: despite promising results in preclinical studies, there is still a lack of clinical evidence¹. We are quoting that because it is the accurate summary of the field, not despite it.

The human evidence: two studies, ten patients

Whitehouse et al., 2017¹² — first-in-human, open-label, no control group, five patients with avascular (white-zone) tears. Autologous MSCs from an iliac crest biopsy were expanded, seeded onto a collagen scaffold, implanted into the tear and repaired with vertical mattress sutures. Followed for two years:

• Three of five patients were asymptomatic at 24 months, with no MRI evidence of recurrent tear
• Two of five required a subsequent meniscectomy due to retear or non-healing, at approximately 15 months after implantation
• No other adverse events occurred

That second bullet is the one that matters most for a decision. Forty percent of the patients in the leading study of this treatment ended up having the operation the treatment was intended to avoid — and it took over a year to find out. The authors' own conclusion is appropriately narrow: undifferentiated MSCs could provide a safe way to augment avascular meniscal repair in some patients.

Sekiya et al., 2019¹³ — first-in-human, no control group, five patients with complex degenerative tears of the medial meniscus. The meniscus was surgically repaired, and autologous synovial MSCs were transplanted two weeks later. At two years, Lysholm, KOOS pain / daily living / sports activity, and Numerical Rating Scale scores were all significantly improved.

• Three adverse events were recorded: raised C-reactive protein, joint effusion, and localised warmth of the knee. The authors note these could have been due to the repair surgery itself
• The authors describe the results as pilot data for a future prospective study

What does not exist

We searched the published literature specifically for anything stronger. As of 2026:

• There is no randomised controlled trial of MSC therapy for meniscal tears
• There is no placebo- or sham-controlled trial
• There is no systematic review of clinical outcomes, because there are not enough clinical outcomes to review
• There is no published data on return to sport after MSC-augmented treatment

⚖️ That is an absence of evidence, not evidence of absence. It does not show the treatment fails. It means the study that would settle it has not been done — and that anyone quoting you a success rate for this treatment is quoting something other than published human data.

Our position, stated plainly

We offer MSC therapy for selected meniscal tears. We think the rationale is coherent, the two published safety signals were acceptable, and it is a defensible option for a narrow group who have understood how early the evidence is.

That is a judgement about promise, not a claim of proof. If what you want is the treatment with the best evidence behind it for a degenerative lesion, the honest answer is structured exercise therapy. If you have a repairable traumatic tear, the honest answer is repair.

Is Regenerative Therapy Right for You?

May be appropriate

• Persistent symptoms after a genuine course of exercise-based rehabilitation — not instead of it
• White-zone tears where repair alone has a poor prognosis and the alternative on the table is resection
• Mild to moderate osteoarthritis (Kellgren-Lawrence 1-2)
• Patients who have understood and accepted that the human evidence is ten uncontrolled patients^12,13

Not appropriate

• ⛔ Bucket-handle tear with a locked knee — this needs urgent surgical assessment, not an injection
• ⛔ Root tear with significant extrusion — usually requires surgical fixation
• ⛔ Advanced osteoarthritis (Kellgren-Lawrence 3-4)
• ⛔ Knee instability requiring concurrent ligament reconstruction
• ⛔ Active infection or significant systemic illness
• ⛔ Symptoms of less than three months in a degenerative lesion — most of these settle with loading and time, and we will tell you to wait

Factors that plausibly affect outcome

Stated as clinical reasoning rather than as findings, because none has been tested in a controlled trial of this treatment: tear location relative to blood supply, tear pattern and size, chronicity, the degree of underlying osteoarthritis, limb alignment, and compliance with rehabilitation.

The Sterling-Certified Approach

The 7-Night Treatment Protocol

Day 1: Assessment

• Comprehensive blood panel and inflammatory marker assessment
• Review of imaging and of what has already been tried, including whether a structured loading programme has been completed
• PRP preparation if indicated

Day 2: Physician consultation and first MSC session

• Bloodwork reviewed by partner clinic physicians
• Treatment plan agreed: 50 million umbilical cord-derived MSCs, or 100 million split across two sessions
• Fresh, not frozen; each batch supplied with a Certificate of Analysis documenting viability and sterility
• Image-guided delivery

Day 5-6: Second session (where 100 million total is planned)

• The second 50 million MSCs are administered, with a 48-72 hour gap between sessions

Days 3-7: Rehabilitation and review

• Structured rehabilitation protocol — the component with the strongest evidence behind it^3,9
• Progress monitoring and discharge planning

⚠️ On cell numbers and dosing: cell counts, viability thresholds and session structure are specifications of what we provide. They are not evidence of effect, and we are not aware of published human data establishing an optimal dose, an optimal interval, or a difference in outcome between fresh and frozen cells in this condition.

Additional therapies we offer

Some patients are offered NK/NKT cell therapy, plasmapheresis, cord blood plasma, or immunokine therapy alongside the core protocol.

⚠️ We want to be direct about these. There is no published evidence that any of them improves meniscal healing. The general observation that systemic inflammation can impair local tissue repair is true, but it does not establish that any specific one of these treatments helps a torn meniscus, and we make no such claim. They are offered for their own reasons, on separate assessment, and none is a reason to choose this over another course of treatment.

⚠️ Note on scheduling: NK/NKT cell therapy requires cell culturing and an extended stay of 21-28 days — three to four times the length of the standard programme.

What to Expect: Recovery Timeline

Individual recovery varies substantially. This reflects our rehabilitation planning and the follow-up schedule used in the published studies^12,13, not a promised outcome.

⚠️ In Whitehouse's series, the two treatment failures declared themselves at around 15 months¹². A good result at six months is encouraging but not conclusive, and follow-up should extend well beyond the end of formal rehabilitation.

Frequently Asked Questions

Q: Do I need surgery for a meniscus tear?

A: It depends entirely on which kind of tear you have. A locked knee from a displaced bucket-handle tear needs urgent surgical assessment. A repairable traumatic tear in a young active knee is usually best repaired. A degenerative lesion is different: in a double-blind trial, arthroscopic meniscectomy did not outperform sham surgery at 12 months or at 5 years^4,5, and guidelines recommend against it for degenerative knee disease⁸.

Q: Can a meniscus tear heal without surgery?

A: Tears in the vascular outer third can heal, with or without repair. Tears in the avascular inner two-thirds largely cannot heal on their own¹. Separately — and this is not the same question — many people with degenerative lesions improve substantially without any operation, which is what the placebo-controlled and physiotherapy-controlled trials demonstrate^4,7.

Q: Can stem cells repair a torn meniscus?

A: Not established. The mechanistic case comes from laboratory and animal work, and the review of that literature states that clinical evidence is still lacking¹. The human data is two uncontrolled studies of five patients each^12,13. In one, three of five patients were asymptomatic at two years and two required a meniscectomy at around 15 months¹².

Q: You sell this treatment. Why are you arguing against it?

A: We are not arguing against it — we are describing it accurately. We think it is a reasonable option for a narrow group of patients who have exhausted better-evidenced alternatives and who understand the evidence is early. Blurring that into "proven" would not help you decide, and you would find out the truth from someone else eventually.

Q: How does stem cell therapy compare to PRP for meniscus tears?

A: PRP delivers growth factors; MSC therapy delivers living cells. Whether either improves meniscal healing in humans has not been established by controlled trials, and no study directly compares them in this condition. Anyone ranking them for you is reasoning from mechanism, not from data.

Q: Will I need multiple treatments?

A: Most patients receive a single session; some are offered 100 million cells split across two. There is no trial evidence on repeat dosing in this condition, so any recommendation for further treatment is a clinical judgement rather than a protocol derived from data.

Q: Is stem cell therapy FDA-approved for meniscus tears?

A: No. It is considered investigational in the United States and is not FDA-approved for this indication. Sterling-certified partner clinics operate under international regulatory frameworks that permit cellular therapy applications.

Q: What if it doesn't work?

A: Surgical options remain available, and prior cell therapy does not preclude subsequent repair or meniscectomy. In the published series, the patients who did not heal went on to meniscectomy without apparent complication from the earlier treatment¹².

Q: Can I run marathons after treatment?

A: There is no published data on return to sport after MSC therapy for meniscal tears. What is known is that outcomes after meniscus surgery depend heavily on which procedure and which meniscus¹¹. Individualised goals are set for each person; we do not guarantee activity levels.

Take the Next Step

Understanding which kind of tear you have is the first and most important step — and for a large group of patients, the best-supported next move is not a procedure at all.

Want an honest assessment?

Take the 2-minute Joint Health Assessment. The medical team reviews each one personally.

If you have a locked knee, do not wait for an assessment — seek urgent orthopaedic care. If your symptoms are recent, or you have not yet completed a structured loading programme, we will tell you to do that first.

[Take the Joint Health Assessment →]